There’s been increasing interest in using Health Technology Assessment to guide coverage decisions and health policies. Recently, the COVID-19 experience has provided important lessons for value assessment of new interventions and its communication to stakeholders.

Precision’s Jeroen Jansen explores several of these lessons and outlines recommendations for future improvement. Part of the Health Affairs Forefront short series, “Value Assessment: Where Do We Go Post-COVID?”

Read the full article here!